Gossamer Bio Inc
Suletud
SektorTervishoid
0.14 -12.5
Ülevaade
Aktsiahinna muutus
24h
Min
0.14
Max
0.16
Sissetulek | 64M 17M |
|---|---|
Müük | -7.7M 9.2M |
Aktsiakasum | -0.2 |
Kasumimarginaal | 182.94 |
Töötajad | 161 |
EBITDA | -28M -71M |
Järgmine tulemuste avaldamine | 3. nov 2026 |
|---|
Turukapital | -391K 86M |
|---|---|
Eelmine avamishind | 12.64 |
Eelmine sulgemishind | 0.14 |
Uudiste sentiment
By Acuity
76%
24%
315 / 339 Pingereas Healthcare
Gossamer Bio Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Gossamer Bio Inc Prognoos
Sentiment
By Acuity
315 / 339 Pingereas Tervishoid
Uudiste sentiment
Väga tugevad languse märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Üle keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.